Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
20
BCTX Quote, Financials, Valuation and Earnings
Last price:
$9.00
Seasonality move
:
3384.88%
Day range:
$8.95 - $9.27
52-week range:
$6.00 - $98.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.57x
Volume:
18K
Avg. volume:
50K
1-year change:
-89.8%
Market cap:
$15.7M
Revenue:
--
EPS (TTM):
-$48.35
Analysts' Opinion
-
Consensus RatingBriaCell Therapeutics Corp. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $95.00, BriaCell Therapeutics Corp. has an estimated upside of 1575.98% from its current price of $8.95.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $40.00 representing 100% downside risk from its current price of $8.95.
Fair Value
-
According to the consensus of 1 analyst, BriaCell Therapeutics Corp. has 1575.98% upside to fair value with a price target of $95.00 per share.
BCTX vs. S&P 500
-
Over the past 5 trading days, BriaCell Therapeutics Corp. has underperformed the S&P 500 by -6.28% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
BriaCell Therapeutics Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
BriaCell Therapeutics Corp. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter BriaCell Therapeutics Corp. reported revenues of --.
Earnings Growth
-
BriaCell Therapeutics Corp. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter BriaCell Therapeutics Corp. reported earnings per share of -$4.35.
Enterprise value:
4.9M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-0.17x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$106.6K
Return On Assets:
-202.82%
Net Income Margin (TTM):
--
Return On Equity:
-318.28%
Return On Invested Capital:
-318.28%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-10-31 | 2024-10-31 | 2025-10-31 | 2024-10-31 | 2025-10-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$15.3K | -$106.7K | -$106.6K | -$26.7K | -$26.7K | |
| Operating Income | -$26.4M | -$30M | -$30.4M | -$5.2M | -$8.3M | |
| EBITDA | -$26.4M | -$29.9M | -$30.3M | -$5.1M | -$8.3M | |
| Diluted EPS | -$1.73 | -$0.88 | -$48.35 | -$0.22 | -$4.35 | |
| Period Ending | 2021-10-31 | 2022-10-31 | 2023-10-31 | 2024-10-31 | 2025-10-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $55.9M | $38.2M | $18.4M | $8.2M | $11.3M | |
| Total Assets | $56.2M | $38.5M | $18.6M | $10.4M | $13.1M | |
| Current Liabilities | $431.4K | $974K | $1M | $5M | $3.3M | |
| Total Liabilities | $764.6K | $28.1M | $16.1M | $6.7M | $3.7M | |
| Total Equity | $55.4M | $10.3M | $2.5M | $3.7M | $9.4M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-10-31 | 2024-10-31 | 2025-10-31 | 2024-10-31 | 2025-10-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$27.8M | -$23.5M | -$29.3M | -$7M | -$7.7M | |
| Cash From Investing | -- | -$753.7K | -$7.8M | -$75K | -$75K | |
| Cash From Financing | $4M | $16.3M | $34.2M | $12M | -- | |
| Free Cash Flow | -$27.8M | -$24M | -$29.3M | -$7M | -$7.7M | |
BCTX
Sector
Market Cap
$15.7M
$27.9M
Price % of 52-Week High
9.11%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
-176.99%
-1.49%
1-Year Price Total Return
-89.8%
-16.66%
Beta (5-Year)
1.385
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$9.44
200-day SMA
Sell
Level
$21.11
Bollinger Bands (100)
Sell
Level
7.62 - 11.76
Chaikin Money Flow
Sell
Level
-10M
20-day SMA
Sell
Level
$10.12
Relative Strength Index (RSI14)
Sell
Level
42.88
ADX Line
Sell
Level
15.68
Williams %R
Buy
Level
-91.1894
50-day SMA
Sell
Level
$10.62
MACD (12, 26)
Sell
Level
-0.32
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Neutral
Level
7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-8.6702)
Sell
CA Score
(Annual)
Level (-9.0882)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (14.7304)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.
Stock Forecast FAQ
In the current month, BCTX has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BCTX average analyst price target in the past 3 months is $95.00.
-
Where Will BriaCell Therapeutics Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that BriaCell Therapeutics Corp. share price will rise to $95.00 per share over the next 12 months.
-
What Do Analysts Say About BriaCell Therapeutics Corp.?
Analysts are divided on their view about BriaCell Therapeutics Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BriaCell Therapeutics Corp. is a Sell and believe this share price will drop from its current level to $40.00.
-
What Is BriaCell Therapeutics Corp.'s Price Target?
The price target for BriaCell Therapeutics Corp. over the next 1-year time period is forecast to be $95.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BCTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for BriaCell Therapeutics Corp. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of BCTX?
You can purchase shares of BriaCell Therapeutics Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BriaCell Therapeutics Corp. shares.
-
What Is The BriaCell Therapeutics Corp. Share Price Today?
BriaCell Therapeutics Corp. was last trading at $9.00 per share. This represents the most recent stock quote for BriaCell Therapeutics Corp.. Yesterday, BriaCell Therapeutics Corp. closed at $8.95 per share.
-
How To Buy BriaCell Therapeutics Corp. Stock Online?
In order to purchase BriaCell Therapeutics Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get BCTX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BCTX
Sector
P/E ratio
--
23.85x
PEG ratio
0.00x
-0.01x
P/B ratio
1.57x
1.81x
Price / LTM sales
--
1.58x
Growth Metrics
BCTX
Sector
Revenue growth
--
4.62%
Earnings growth
-1897.89%
10.5%
Revenue (5-year growth)
--
6.5%
Earnings forecast
--
-$0.21
Profitability
BCTX
Sector
Profitability FY 2025
-$106.6K
$3.6M
Return on invested capital
-318.28%
-31.87%
Return on assets
-202.82%
-28.18%
Return on equity
-318.28%
-37.63%
Earnings Date
Last Earnings Date
Dec
21
Next Earnings Date
Dec
21
Estimated Next Earnings Date
Mar
22
Balance Sheet
BCTX
Sector
Total cash
$10.2M
$26.4M
Short term investments
--
$25.7M
Total assets
$21.6M
$76.9M
Long term debt
--
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
